Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma

PURPOSE: Bevacizumab treatment at 7.5 mg/kg every 3 weeks results in improved hearing in approximately 35%-40% of patients with neurofibromatosis type 2 (NF2) and progressive vestibular schwannomas (VSs). However, the optimal dose is unknown. In this multicenter phase II and biomarker study, we eval...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Plotkin, Scott R., Duda, Dan G., Muzikansky, Alona, Allen, Jeffrey, Blakeley, Jaishri, Rosser, Tena, Campian, Jian L., Clapp, D. Wade, Fisher, Michael J., Tonsgard, James, Ullrich, Nicole, Thomas, Coretta, Cutter, Gary, Korf, Bruce, Packer, Roger, Karajannis, Matthias A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2019
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7098833/
https://ncbi.nlm.nih.gov/pubmed/31626572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01367
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados